Anti-STING Agonistic Antibody Introduction

Currently, tumor immunotherapy has achieved great clinical success. In particular, immune checkpoint blockade therapies represented by PD-1/PD-L1 and CTLA-4 are widely used. However, it has been clinically found that most cancer patients whose tumor's immune microenvironment is in a state of suppression are resistant to immunosuppressant therapies. Therefore, scientists have shifted their research direction to the development of agonistic antibody therapies. Activation of stimulator of interferon genes (STING) can induce the production of type I interferon and regulate the downstream gene products to improve the immunosuppressive microenvironment of tumors and also synergize with immune checkpoint inhibitors to increase the immune response rate. Based on the key role of the STING pathway in immunotherapy, a variety of STING agonists have entered the clinical research stage, and the activation of the STING pathway is a promising approach for cancer treatment. Based on our rich field experience and advanced research platform, Creative Biolabs provides comprehensive services to support custom agonistic antibodies and checkpoint agonistic antibodies.

Fig 1. Activation of the immune response: antigen presenting cell activates T-lymphocytes.

Anti-STING Agonistic Antibody

STING is an important target molecule that regulates innate immune function. Cyclic guanosine monophosphate adenylate synthase (cGAS) recognizes exogenous DNA. The cGAS-cGAMP-STING signaling pathway involved in the two enzymes plays an important role in the production of type I interferon and inflammatory cytokines, as well as the activation of antigen-presenting cells, which in turn promotes the initiation and recruitment of tumor-specific CD8⁺ T cells. Improving the tumor immunosuppressive microenvironment can also cooperate with immune checkpoint inhibitors to improve the immune response rate. Therefore, STING agonists are expected to be used as a new class of immunotherapy or in combination with immune checkpoint inhibitors for anti-tumor treatment.

Based on the key role of the STING pathway in immunotherapy, a variety of STING agonists have entered the clinical research stage, and activating the STING pathway is a promising method for cancer treatment. At present, anti-STING agonists include nucleotide-based small molecules and anti-SITNG antibodies. Nucleotide compounds are small molecules, have large polarity, and have a very short half-life when injected intravenously, which makes them easy to degrade by enzymes or quickly removed by metabolism. Intratumoral injection is often used in clinical research, but it is difficult to enter cells and cannot cope with the common difficulties of tumor recurrence and metastasis, so its clinical application faces great challenges. The new generation of STING agonists is represented by non-nucleotide drugs. However, because STING protein is widely expressed in immune cells and non-immune cells, systemic application of STING is likely to induce the production of inflammatory cytokines, leading to inflammatory diseases and autoimmune diseases and even the risk of "cytokine storms".

In recent years, various anti-STING agonist antibodies have also been produced and used in a range of cancer agonist antibody therapies. Studies have shown that STING agonist antibodies have an important role in cancer therapy. Currently, steps have also been taken to enhance the antitumor response of anti-STING agonist antibodies by using several drugs or by adding some antibodies. These approaches can effectively enhance the effect of induced immune responses in tumor models.

Taken together, there is an urgent need to develop novel STING agonist antibodies with tumor/immune organ targeting capabilities to improve the efficiency of tumor-specific immune activation while reducing side effects.

Creative Biolabs has a wealth of knowledge and experience in antibody discovery. We would be happy to share with you our knowledge and experience in agonistic antibody discovery and anti-STING agonistic antibody discovery.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: